Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, today announced the appointment of Dr. Noel Monks as the company's Head of Biology. Dr. Monks joins Ratio with over 20 years of experience in drug discovery, development, and translational medicine in the fields of oncology and rare diseases.
"We are thrilled to welcome Noel to our growing team of world-class experts in radiopharmaceuticals discovery and development," said Dr. John Babich, Ratio's President and Chief Scientific Officer. "Noel's experience with preclinical drug discovery and development will be instrumental to advancing Ratio's pipeline candidates to clinical studies. His expertise will help us develop further our proprietary radiotherapeutic platforms, Trillium™ and Macropa™, and create new partnerships with pharmaceutical companies in the cancer therapy space."
Prior to joining Ratio, Dr. Monks held roles as Senior Director of Preclinical Biology and Pharmacology at NeuBase Therapeutics and Associate Director at AstraZeneca/Medimmune. He has extensive experience in leading in vitro and in vivo pharmacology teams and delivering IND-enabling preclinical data packages across a broad portfolio of projects and therapeutic modalities including, biotherapeutics, small molecules, cell therapies and genetic medicines.
"I am fortunate and excited to bring my expertise, enthusiasm and passion to Ratio as the company enters this exciting new chapter: moving into the clinical stages of development for its proprietary platforms," remarked Dr. Monks.
Dr. Monks holds a Ph.D. in Cancer Pharmacology and Drug Development from the University of Newcastle upon Tyne, U.K.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!